While anti‐tumor activity was observed across multiple subgroups in this study, we noted a trend towards higher ORR for patients harboring EGFR ex20ins versus other EGFR tumor mutations (41.7% vs 33.3%). The gene discussed is EGFR; the disease is neoplasm.